Immunotherapy: An Old and New Modality for the Treatment of Cancer

Employing a patient's own immune system for the treatment of cancer has been a promise for more than a century. Antibodies targeting programmed death 1 and other inhibitory receptors expressed on T cells, cancer cells, and other immune cells have demonstrated antitumor activity across solid and hematologic malignancies, leading to a number of approvals by regulatory agencies. These antibodies, also called immune checkpoint inhibitors (ICIs), can achieve durable tumor responses, sometimes lasting several years.

http://bit.ly/2RijDlm